The Strategic Dilemma Faced By The Ceo Of A Start Up Company

When a certain point is reached regarding a company’s success, a set of different opportunities arise and partnerships may unfold. However, with every possible strategy available, risks and benefits also come into play; without discarding any of them beforehand, every option is a strong candidate until a final decision is made. In this case study we will analyze the current business strategy pertaining

• Analysis of the target company—is the company a strategic fit as far as size, geographic location, business mix, operational capacity, financial strength and availability for takeover.

This document was prepared by Frances Tuer and edited by Jacqueline Glenney and Michael Robertson. It was designed to help students in MGMT 1P96 understand the case analysis process.

“Case studies are stories. It presents a realistic, complex, and contextually rich situations and often involve a dilemma, conflict, or problem that one or more of the characters in the case must negotiate”,

Known as one of the world’s most deadly diseases, second only to heart disease, cancer is a well known killer. Cancer is a disease mankind has been burdened with since the first documented records of human existence (“The History of Cancer”). Until the early 1900s, cancer was exclusively treated with surgery, which didn’t usually yield very effective results. Only recently have doctors reached a point where they can use drug therapies to suppress the disease. Relative to humans, cancer treatments are very new. Because the market for pharmaceutical drugs is so new, they lack many regulations and pricing guidelines. This allows these new companies to create a drug and place almost any price on it. The system in place can very easily be taken

A formal, in-depth case study analysis requires you to utilize the entire strategic management process. Assume your group is a consulting team asked by the ABC Corporation to analyze its external/internal environment and make strategic recommendations. You must include exhibits to support your analysis and recommendations.

First, they need to review their strategic plan. If they didn’t complete a situation analysis before deciding on the buyout, they should now. Special attention should be placed on environmental scanning as they will be entering new markets, so it is important to understand their target markets. Second, they need to evaluate their mission statement, vision, and value proposition to assess whether they are accurate and reflect who the company is. Third, they need to re-evaluate an existing business-unit strategy or develop a new one if the situation warrants.

In the medical industry the assessment process shares common qualities like all business investments when it comes determining its value. In preparing for the sale, keep in mind that it’s harder to start a practice from scratch than to acquire one already established. Acquisitions are good business strategies for eliminating the competition or acquiring a larger share of the market. Sometimes it’s a method of expanding the practice into other segments of medical services for an existing practice. For the seller, this strategy creates a bidders

Strategic Choices prevails in many companies’ setting to progress towards betterment. Somehow it comes with benefits and opportunity costs as well. Based on the case study for this week, Biocon India, a pharmaceutical company in India, is being faced with a strategic choice to proliferate but as mentioned, it comes with costs. Today this essay will scrutinize this case in terms of the strategic choices availability, the key groups involved and their relationship, the risks and rewards for growing Biocon, the primary structure of Biocon, the threats for such a structure, and my recommendation to the company.

Roche-Genetech is a biotechnology research company that created MORPHEUS which is a Phase 1b/2 new pancreatic cancer immunotherapy development

In an exclusive interview posted on Inspirery, Dr. Clay Siegall, the CEO of Seattle Genetics, explains why he has focused on targeted therapies for cancer. Siegall, who holds a Ph.D in genetics from George Washington University, co-founded the biotech company to update cancer treatments so that chemotherapy is not so traumatic for cancer patients. Since Seattle Genetics's first ADC, which targets cancer cells as opposed to both cancer and healthy cells, became FDA-approved, Siegall has generated substantial revenue for company by arranging licensing agreements. They took a risk, said Siegall, since only one out of every ten drugs submitted to the FDA receives their approval. Under Siegall's leadership, Seattle Genetics is developing a diverse

This case gives comprehensive coverage of a firm’s decision to start an initial public offering but also to go through the process of going public. TRX is a company managing travel-and-data processing activities for its clients. Its target market has significant transaction volume in travel agencies, travel suppliers, large corporation and credit-card issuer. Regarding its service offerings, it focuses on transaction processing, data integration and customer care. Its fortune tied to the overall health of travel industry. TRX generates a lot of revenue but less profit. Trip Davis, Chief Executive Officer of TRX, Inc. decided it was time to raise capital in order to fund the growth of the company. His main focus was to accomplish a strategic recapitalization of TRX. This case gives a brief history about several events from the company’s incorporation in 1999 through the completion of an IPO in September 2005. The main goal is to raise capital but there is also a consideration of another reason for going public. In November 1999, they tried to go public but the IPO was never finalized. After the failed IPO, Trip Davis and TRX president decided to focus on strategic investors in order to raise $20 million convertible into equity at $11 per share. In 2004, he believed that Sabre, Inc. one of the largest strategic investors was not working for the best interest of the company. He took into consideration three possible capital raising options: IPO, private placement of equity, or

Group President, Worldwide Biopharmaceuticals Businesses, 2006-2010 Led commercial businesses in Europe, Canada, Latin America, Africa and Middle East Regions, 2000-2006 Led Latin America and Canada

Unlike Gilead that has only one product in its Oncology line, Bristol-Myers Squibb presently have four different drugs namely: Erbitux –an epidermal growth factor receptor (EGFR) antagonist for the treatment of Head & Neck cancer and Colorectal cancer,(2) Opdivo (nivolumab) for the treatment of unresectable or metastic melanoma and lungs cancer, (3) Syrcel( dasatinb) for the treatment of newly diagnosed adult with Philadelphia chromosome –positive (ph+) chronic myeloid leukemia and (4) Yervoy (ipilimumob) for the treatment of melanoma a type of skin cancer that spread and as such cannot be remove by surgery. Like Seattle Genetics, the company products use either Antibody-drug Conjugate (ADC) though in a different version by linking potent cytotoxic to monoclonal antibodies targeted to specific tumor cells or immune-oncology, an innovative technology that unlocks the body own immune system to fight against cancerous cells. It also expanded its focus to Nolch inhibitor (used in blocking powerful pathway that promotes tumor cell survival for certain other types of cancer. (Bristol-Myer Squibb, 2014) Because the technology is similar but used differently, BMS would be considered a close competitor who currently has the advantage of having four targeted specific drugs and 12 other oncology and immune-oncology in various trial phases.

One company in Utah which stands out above others is the Sweet Tooth Fairy bakery. This bakery started out as a single bakery in Draper, Utah and now includes locations all over the state, such as shops open in Provo, St. George, Midvale, Orem, Salt Lake City, Layton, West Valley City, and Murray. There's even a new shop open in Scottsdale, Arizona, which indicates that the company truly has the potential to expand nationwide. Even though the field of bakeries is a truly congested and competitive, The Sweet Tooth Fairy bakery has managed to create some real innovation in the field, so that it stands far out from the competition. This is one of the main reasons for this company's success its creativity. As The Sweet Tooth Fairy website explains, "Forgetting ingredients or adding an extra pinch here and there is often how she discovers her most incredible delicacies. Her picturesque shops are beautifully filled with everything from cookies to cupcakes and anything in between. Young and old alike are drawn to her exquisite desserts that seem to have been created just for them." Thus, the creativity that this store has in creating baked goods that are one of a kind is a way to make all customers feel special.